US98978V1035
© BusinessWire
11.12.2025
ZTS
LISTED
NYSE
Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase
News Preview
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 20, 2...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
ZTS
LISTED
NYSE
Zoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in Cats
News Preview
Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain relief with a single injection, Portela targets anti-nerve growth factor (NGF), which is a key mediator of OA pain and inflammation.
In a...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2025
ZTS
LISTED
NYSE
Zoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation Webcast
News Preview
Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to provide an update on its proven innovation model, robust and diversified R&D pipeline, and upcoming growth catalysts as the company continues pioneering the future of animal health.
“The pace of animal health innovation...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
26.11.2025
ZTS
LISTED
NYSE
Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
News Preview
Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs.
Lenivia is a new antibody therapy that reduces OA pain in dogs for three months with one injection through its novel binding properties to nerve...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
20.11.2025
ZTS
LISTED
NYSE
Zoetis to Participate in the Piper Sandler 37th Annual Healthcare Conference
News Preview
Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. Kristin Peck, Chief Executive Officer and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts.
Investors and other intere...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2025
ZTS
LISTED
NYSE
Zoetis to Host Innovation Webcast
News Preview
Zoetis Inc. (NYSE:ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025, featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Executive Vice President and Chief Financial Officer; Rob Polzer, Ph.D., Executive Vice President and President of Research and Development; and Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ZTS
LISTED
NYSE
Zoetis Announces Third Quarter 2025 Results
News Preview
Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2025.
The company reported revenue of $2.4 billion for the third quarter of 2025, an increase of 1% compared with the third quarter of 2024. On an organic operational1 basis, revenue for the third quarter of 2025 increased 4% compared with the third quarter of 20...
Themefolio
Profiler
Peergroup
© BusinessWire
03.11.2025
ZTS
LISTED
NYSE
Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026
News Preview
Zoetis Inc. (NYSE: ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed K...
Themefolio
Profiler
Peergroup
© BusinessWire
29.10.2025
ZTS
LISTED
NYSE
Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
News Preview
Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing interval approved for the alleviation of pain associated with osteoarthritis (OA) in cats.
Designed to provide three months of OA pain...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2025
ZTS
LISTED
NYSE
Zoetis Appoints Stephanie Tilenius to its Board of Directors
News Preview
Zoetis Inc. (NYSE: ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board.
Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2025
ZTS
LISTED
NYSE
Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs
News Preview
Zoetis Inc. today announced that Health Canada has approved Lenivia® (izenivetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in dogs. Built on a decade of science and research, Lenivia is a new antibody therapy with a safety profile demonstrated in a nine-month field study where dogs receiving Lenivia experienced in...
Themefolio
Profiler
Peergroup
© BusinessWire
10.10.2025
ZTS
LISTED
NYSE
Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs
News Preview
Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Based on the CVMP’s positive opinion, th...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
09.10.2025
ZTS
LISTED
NYSE
Zoetis Declares Fourth Quarter 2025 Dividend
News Preview
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on Tuesday, December 2, 2025, to all holders of record of the Company’s common stock as of the close of business on Friday, October 31, 2025.
About Zoetis
As the world’s leading animal health com...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ZTS
LISTED
NYSE
Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle
News Preview
Zoetis Inc. today announced that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from the U.S. Food and Drug Administration for the prevention and treatment of infestations caused by the larvae of Cochliomyia hominivorax (myiasis), and prevention of reinfestation for 21 days. This conditional...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2025
ZTS
LISTED
NYSE
Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results
News Preview
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, November 4, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2025 financial results and respond to questions from financial analysts during the call.
Investors an...
Themefolio
Profiler
Peergroup
© BusinessWire
12.09.2025
ZTS
LISTED
NYSE
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
News Preview
Zoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for Portela® (relfovetmab), a new monoclonal antibody (mAb) therapy intended for the alleviation of pain associated with osteoarthritis (O...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2025
ZTS
LISTED
NYSE
Zoetis to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
News Preview
Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8 at 1:05 p.m. ET.
Investors and other interested parties can access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentation...
Themefolio
Profiler
Peergroup
© BusinessWire
01.07.2025
ZTS
LISTED
NYSE
Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results
News Preview
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review second quarter 2025 financial results and respond to questions from financial analysts during the call.
Investors and...
Themefolio
Profiler
Peergroup
© BusinessWire
05.06.2025
ZTS
LISTED
NYSE
Zoetis Releases 2024 Sustainability Progress Update
News Preview
Zoetis published its 2024 Sustainability Progress Update “Advancing Sustainability in Animal Health for a Better Future” to highlight the company’s continued progress toward achieving its Driven to Care aspirations. The publication represents Zoetis’ fifth year reporting on its purpose-driven actions across three pillars – Communities, Animals and...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
ZTS
LISTED
NYSE
Dr. Mark Stetter Elected to Zoetis Board of Directors
News Preview
Zoetis Inc. (NYSE: ZTS) today announced the election of Dr. Mark Stetter to its Board of Directors, effective as of the company’s annual shareholder meeting on May 21, 2025.
Dr. Stetter brings extensive experience in veterinary medicine and animal health, including as Dean of the University of California, Davis School of Veterinary Medicine, to t...
Themefolio
Profiler
Peergroup
© BusinessWire
21.05.2025
ZTS
LISTED
NYSE
Zoetis Declares Third Quarter 2025 Dividend
News Preview
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the third quarter of 2025. The dividend will be paid on Wednesday, September 3, 2025, to all holders of record of the Company’s common stock as of the close of business on Friday, July 18, 2025.
About Zoetis
As the world’s leading animal health compan...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
ZTS
LISTED
NYSE
Zoetis to Participate in Upcoming Investor Conferences
News Preview
Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences.
BNP Paribas Animal Health Day on May 22, 2025 at 1:00 p.m. ET
Stifel 2025 Jaws and Paws Conference on May 29, 2025 at 9:10 a.m. ET
William Blair 45th Annual Growth Stock Conference on June 3, 2025 at 10:40 a.m...
Themefolio
Profiler
Peergroup
© BusinessWire
06.05.2025
ZTS
LISTED
NYSE
Zoetis Announces First Quarter 2025 Results
News Preview
Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2025 and updated its full year 2025 guidance.
The company reported revenue of $2.2 billion for the first quarter of 2025, an increase of 1% compared with the first quarter of 2024. On an organic operational1 basis, revenue for the first quarter of 2025 increased...
Themefolio
Profiler
Peergroup
© BusinessWire
27.03.2025
ZTS
LISTED
NYSE
Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results
News Preview
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call.
Investors and the...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
ZTS
LISTED
NYSE
Zoetis to Participate in Upcoming Investor Conferences
News Preview
Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences.
Bank of America Securities 2025 Animal Health Summit on Thursday, February 27, 2025 at 1:20 p.m. ET.
Barclays Global Healthcare Conference on Tuesday, March 11, 2025 at 10:30 a.m. ET.
Investors and other inter...
Themefolio
Profiler
Peergroup
© BusinessWire
14.02.2025
ZTS
LISTED
NYSE
Zoetis Receives Conditional License from USDA for Avian Influenza Vaccine, H5N2 Subtype, Killed Virus
News Preview
Zoetis today announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is labelled for use in chickens. The conditional license was granted on the demonstration of safety, purity, and reasonabl...
Themefolio
Profiler
Peergroup
© BusinessWire
13.02.2025
ZTS
LISTED
NYSE
Zoetis Reports Fourth Quarter and Full Year 2024 Results
News Preview
Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2024 as well as provided full year guidance for 2025.
The company reported revenue of $2.3 billion for the fourth quarter of 2024, an increase of 5% compared with the fourth quarter of 2023. On an operational1 basis, revenue for the fourth quarter o...
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2025
ZTS
LISTED
NYSE
Zoetis Declares Second Quarter 2025 Dividend
News Preview
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the second quarter of 2025. The dividend will be paid on Tuesday, June 3, 2025, to all holders of record of the Company’s common stock as of the close of business on Monday, April 21, 2025.
About Zoetis
As the world’s leading animal health company,...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
ZTS
LISTED
NYSE
Zoetis Announces U.S. Label Update for Librela® (bedinvetmab injection), a Treatment to Control Canine Osteoarthritis (OA) Pain
News Preview
Zoetis Inc. today announced that it has updated the U.S. label for Librela® (bedinvetmab injection), following its submission of a supplement to the U.S. Food and Drug Administration (FDA). This supplement includes updated labeling based on post-approval experience with Librela in the U.S. since the product launched over a year ago. The company re...
Themefolio
Profiler
Peergroup
© BusinessWire
07.01.2025
ZTS
LISTED
NYSE
Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2024 Financial Results
News Preview
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 13, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2024 financial results and respond to questions from financial analysts during the cal...
Themefolio
Profiler
Peergroup
© BusinessWire
12.12.2024
ZTS
LISTED
NYSE
Zoetis Declares First Quarter 2025 Dividend; Board Approves 16% Payment Increase
News Preview
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the first quarter of 2025, an increase of 16% from the quarterly dividend rate paid in 2024. The dividend will be paid on Tuesday, March 4, 2025, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 21,...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
ZTS
LISTED
NYSE
Zoetis to Participate in the Piper Sandler 36th Annual Healthcare Conference
News Preview
Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 11:30 a.m. ET.
Investors and other interested parties will be able to access a live...
Themefolio
Profiler
Peergroup
© BusinessWire
11.11.2024
ZTS
LISTED
NYSE
Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role
News Preview
Zoetis Inc. (NYSE:ZTS) today announced the appointment of Jamie Brannan to a newly created role of Chief Commercial Officer, overseeing all commercial markets across the globe for the world’s leading animal health company. In this new role, Mr. Brannan will lead an evolved commercial organizational structure that will accelerate the company’s long...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
ZTS
LISTED
NYSE
Zoetis to Participate in Jefferies London Healthcare Conference
News Preview
Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 3:00 p.m. GMT.
Investors and other interested parties will be able to access a live audio...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
ZTS
LISTED
NYSE
Zoetis Announces Third Quarter 2024 Results
News Preview
Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2024 and raised its full year 2024 guidance for revenue and adjusted EPS.
The company reported revenue of $2.4 billion for the third quarter of 2024, an increase of 11% compared with the third quarter of 2023. On an operational1 basis, revenue for the third quart...
Themefolio
Profiler
Peergroup
© BusinessWire
10.10.2024
ZTS
LISTED
NYSE
Zoetis Declares Fourth Quarter 2024 Dividend
News Preview
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the fourth quarter of 2024. The dividend will be paid on Tuesday, December 3, 2024, to all holders of record of the Company’s common stock as of the close of business on Thursday, October 31, 2024.
About Zoetis
As the world’s leading animal health co...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
ZTS
LISTED
NYSE
Zoetis and Danone Announce Strategic Partnership to Pioneer Sustainable Innovation in Dairy Farming Using the Power of Genetics
News Preview
Zoetis and Danone recently announced a joint business development plan to drive sustainable practices on today’s dairy farms through the power of genetics for healthier cows. Combining Danone’s commitment to environmental stewardship with Zoetis’ expertise in animal genetics, the partnership aims to innovate the dairy industry’s approach to breedi...
Themefolio
Profiler
Peergroup
© BusinessWire
19.09.2024
ZTS
LISTED
NYSE
Zoetis to Host Webcast and Conference Call on Third Quarter 2024 Financial Results
News Preview
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Monday, November 4, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2024 financial results and respond to questions from financial analysts during the call.
Investors and...
Themefolio
Profiler
Peergroup
© BusinessWire
20.08.2024
ZTS
LISTED
NYSE
Zoetis to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 1:05 p.m. ET.
Investors and o...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
